top of page


20Med Therapeutics was founded as a spin-off company out of the University of Twente, based on research of the Biomedical Chemistry group of Johan Engbersen.


Collaboration with Touchlight to establish a novel vaccin platform which combines Touchlight’s rapid enzymatic doggybone DNA platform with 20Med’s bio-responsive polymeric Nanoparticle technology. Touchlight, as part of its funding from the Bill & Melinda Gates Foundation, will further evaluate and determine the potential applicability of this technology combination.


Collaboration with Coalition for Epidemic Preparedness Innovations to advance the development of our bio-responsive polymeric Nanoparticle platform in a project that could end the need for frozen storage of mRNA vaccines.


Investment of 325 million euros from National Growth Fund in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs. As partner within Oncode-PACT, 20Med receives 5 million euros to advance its polymeric Nanoparticle technology for the development of next generation cancer therapies.


Financing round with current shareholders.


Financing round of EUR 3.3. million.

bottom of page